Salvin Dental Specialties Announces the Acquisition of Exactech's Dental Biologics Assets
January 4, 2016 – Salvin Dental Specialties, Inc., through its Salvin Regenerative subsidiary, today announced that it has acquired substantially all of the assets of Exactech Inc.'s dental biologics business.
Salvin Dental Specialties, Inc., a privately held company doing business in over 100 countries, develops, manufactures and markets regenerative biomaterials and surgical instrumentation specifically for implant dentistry.
According to Founder and CEO, Bob Salvin, Exactech has an exciting dental product line, and this acquisition will provide Salvin with greater product depth as well as additional manufacturing capabilities.
Exactech, Inc. (Nasdaq: EXAC) is a publicly traded company that develops and produces bone and joint restoration products for hip, knee, shoulder and spine.
Exactech's Dental Biologics Division supplies the dental market with dental biologic products including Optecure® and Oralife®. Optecure® Dental is an engineered bone graft for reconstruction and augmentation of deficient maxillary and mandibular alveolar ridges and dental intraosseous defects.
Exactech's Senior Vice President and General Manager of Spine and Biologics Bruce Thompson said “We have made the strategic decision to focus more exclusively on our core orthopaedic business, and our long-standing distribution relationship with Salvin gives us confidence that they will take good care of dental customers in their pursuit of improving patient care.”
Financial terms were not disclosed. Deloitte Corporate Finance acted as an advisor to Salvin Dental.